{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:41Z","timestamp":1786120301877,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3,1]]},"DOI":"10.1097\/qai.0b013e31824234d8","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T13:42:56Z","timestamp":1322833376000},"page":"266-273","source":"Crossref","is-referenced-by-count":9,"title":["Intrapartum Single-Dose Carbamazepine Reduces Nevirapine Levels Faster and May Decrease Resistance After a Single Dose of Nevirapine for Perinatal HIV Prevention"],"prefix":"10.1097","volume":"59","author":[{"given":"Eva P.","family":"Muro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quirine","family":"Fillekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elton R.","family":"Kisanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u00eblla","family":"L'homme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey","family":"Mariki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre J. A. M.","family":"Van der Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wil","family":"Dolmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sarah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210131","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.283.9.1175","article-title":". Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.","volume":"283","author":"De Cock","year":"2000","journal-title":"JAMA"},{"key":"R2-7-20210131","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(99)80008-7","article-title":". Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.","volume":"354","author":"Guay","year":"1999","journal-title":"Lancet"},{"key":"R3-7-20210131","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(03)14341-3","article-title":". Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.","volume":"362","author":"Jackson","year":"2003","journal-title":"Lancet"},{"key":"R4-7-20210131","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.qai.0000234089.41785.c8","article-title":". Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women.","volume":"43","author":"Lhomme","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-7-20210131","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.qai.0000167154.37357.f9","article-title":". Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies.","volume":"39","author":"Muro","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-7-20210131","first-page":"283","article-title":". Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.","volume":"38","author":"Cressey","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-7-20210131","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa062876","article-title":". Response to antiretroviral therapy after a single, peripartum dose of nevirapine.","volume":"356","author":"Lockman","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-7-20210131","first-page":"59","article-title":"Nevirapine resistance after single dose prophylaxis.","volume":"4","author":"Eshleman","year":"2002","journal-title":"AIDS Rev"},{"key":"R9-7-20210131","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1086\/499967","article-title":". Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.","volume":"193","author":"Eshleman","year":"2006","journal-title":"J Infect Dis"},{"key":"R10-7-20210131","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":". Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.","volume":"192","author":"Johnson","year":"2005","journal-title":"J Infect Dis"},{"key":"R11-7-20210131","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1086\/526780","article-title":". Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.","volume":"46","author":"Coffie","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R12-7-20210131","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1086\/341300","article-title":". Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.","volume":"186","author":"Cunningham","year":"2002","journal-title":"J Infect Dis"},{"key":"R13-7-20210131","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/QAD.0b013e32810996b2","article-title":". Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.","volume":"21","author":"Chi","year":"2007","journal-title":"AIDS"},{"key":"R14-7-20210131","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1086\/590160","article-title":". Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.","volume":"198","author":"Flys","year":"2008","journal-title":"J Infect Dis"},{"key":"R15-7-20210131","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/QAI.0b013e31814b97e4","article-title":". Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.","volume":"46","author":"McConnell","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-7-20210131","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/00002030-200110190-00006","article-title":". Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).","volume":"15","author":"Eshleman","year":"2001","journal-title":"AIDS"},{"key":"R17-7-20210131","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/0889222041217518","article-title":". Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.","volume":"20","author":"Eshleman","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R18-7-20210131","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1086\/650745","article-title":". Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.","volume":"50","author":"Lallemant","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R19-7-20210131","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/499966","article-title":". Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote dIvoire.","volume":"193","author":"Chaix","year":"2006","journal-title":"J Infect Dis"},{"key":"R20-7-20210131","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/AAC.00910-06","article-title":". Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.","volume":"51","author":"Chaix","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-7-20210131","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(07)61605-5","article-title":". Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.","volume":"370","author":"Chi","year":"2007","journal-title":"Lancet"},{"key":"R22-7-20210131","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/QAI.0b013e3181743969","article-title":". Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.","volume":"48","author":"Chi","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-7-20210131","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32832949d5","article-title":". Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.","volume":"23","author":"Arrive","year":"2009","journal-title":"AIDS"},{"key":"R24-7-20210131","first-page":"138","article-title":". Update of the drug resistance mutations in HIV-1: 2009.","volume":"17","author":"Johnson","year":"2009","journal-title":"Top HIV Med"},{"key":"R25-7-20210131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-4347(00)00231-0","article-title":". Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.","volume":"744","author":"Hollanders","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R26-7-20210131","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00002030-199903110-00006","article-title":". A phase III study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).","volume":"13","author":"Musoke","year":"1999","journal-title":"AIDS"},{"key":"R27-7-20210131","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkn441","article-title":". Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration.","volume":"63","author":"Kunz","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R28-7-20210131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00148581-200002020-00004","article-title":". Anticonvulsants and breast feeding: a critical review.","volume":"2","author":"Bar-Oz","year":"2000","journal-title":"Paediatr Drugs"},{"key":"R29-7-20210131","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jama.292.2.202","article-title":". Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.","volume":"292","author":"Taha","year":"2004","journal-title":"JAMA"},{"key":"R30-7-20210131","first-page":"289","article-title":". PMTCT from research to realityresults from a routine service.","volume":"94","author":"Sherman","year":"2004","journal-title":"S Afr Med J"},{"key":"R31-7-20210131","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4269\/ajtmh.2003.69.447","article-title":". Mother-to-child transmission of human immunodeficiency virus type 1 in relation to the season in Yaounde, Cameroon.","volume":"69","author":"Ayouba","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"R32-7-20210131","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ije\/dym104","article-title":". Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.","volume":"36","author":"Arrive","year":"2007","journal-title":"Int J Epidemiol"},{"key":"R33-7-20210131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcv.2009.02.009","article-title":". Resistance to antiretrovirals in HIV-infected pregnant women.","volume":"45","author":"Weinberg","year":"2009","journal-title":"J Clin Virol"},{"key":"R34-7-20210131","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1365-3156.2005.01526.x","article-title":". High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting.","volume":"10","author":"Manzi","year":"2005","journal-title":"Trop Med Int Health"},{"key":"R35-7-20210131","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/09540120412331319723","article-title":"Exploring socio-economic conditions and poor follow-up rates of HIV-exposed infants in Johannesburg, South Africa.","volume":"17","author":"Jones","year":"2005","journal-title":"AIDS Care"},{"key":"R36-7-20210131","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jbt.20180","article-title":"Mechanisms of cytochrome P450 induction.","volume":"21","author":"Tompkins","year":"2007","journal-title":"J Biochem Mol Toxicol"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e31824234d8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:26:38Z","timestamp":1786047998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201203010-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31824234d8","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3,1]]}}}